Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer

Molecular Oncology

Volumn 3, Issue 5-6, 2009, Pages 409-424

  Gérard, Catherine ^a   Debruyne, Channa ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immunotherapy; Lung cancer; NSCLC; Targeted therapy; Tumor antigen; Tyrosine kinase receptors

Indexed keywords

BELAGENPUMATUCEL L; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CP 751871; CYCLOPHOSPHAMIDE; DOCETAXEL; EGF VACCINE; ERLOTINIB; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; L BLP25 VACCINE; LUCANIX; MAGE A3 ASCI; MELANOMA ANTIGEN 3; MONTANIDE ISA 51; MUCIN 1; NAVELBINE; PACLITAXEL; PAZOPANIB; SORAFENIB; STIMUVAX; SUNITINIB; TAXANE DERIVATIVE; TG 4010; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VX 001;

ACTIVE IMMUNIZATION; ADD ON THERAPY; ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ASTHENIA; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; IMMUNOGENICITY; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION;

EID: 70350571213     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.09.001     Document Type: Review

References (71)

1. Acres B., Quoix E., Ramlau R., Lacoste G., Marie Bastien B., Tavernano A., Bettinger S., Bizouarne N., Limacher J.M., and Bonnefoy J.Y. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J. Clin. Oncol. 27 (2009) 3027 (Abstract)
2. Altorki N., Guarino M., Lee P., Pass H.I., Filip E., Bauer T., Roychowdhuri D., Zaks T., Ottesen L., and Yankelevitz D. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-of-concept phase II study. J. Clin. Oncol. 26 (2008) 7557 (Abstract)
3. + T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 172 (2004) 3289-3296
4. Bauman J.E., Eaton K.D., and Martins R.G. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. Clin. Cancer Res. 13 (2007) s4632-s4636
5. Bauwens O., and Ninane V. New diagnostic techniques in bronchial endoscopy. Rev. Mal. Respir. 24 (2007) 6S28-6S34
6. Bepler G., Begum M., and Simon G.R. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 15 (2008) 130-139
7. Blumenschein Jr. G.R., Khuri F.R., von Pawel J., Gatzemeier U., Miller Jr. W.H., Jotte R.M., Le Treut J., Sun S.L., Zhang J.K., Dziewanowska Z.E., et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J. Clin. Oncol. 26 (2008) 1879-1885
8. Bolonaki I., Kotsakis A., Papadimitraki E., Aggouraki D., Konsolakis G., Vagia A., Christophylakis C., Nikoloudi I., Magganas E., Galanis A., et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25 (2007) 2727-2734
9. Bradbury P.A., Heist R.S., Kulke M.H., Zhou W., Marshall A.L., Miller D.P., Su L., Park S., Temel J., Fidias P., et al. A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 204-211
10. Brichard V.G., and Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert. Opin. Biol. Ther. 8 (2008) 951-968
11. Brugger W., Triller N., Blasinska-Morawiec M., Curescu S., Sakalauskas R., Manikhas G., Mazieres J., Whittom R., Rohr K., and Cappuzzo F. Biomarker analyses from the phase III, placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J. Clin. Oncol. 27 (2009) 8020 (Abstract)
12. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulieres D., Cormier Y., Ellis P., Price A., Sawhney R., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 6674-6681
13. Cappuzzo F., Ciuleanu T., Stelmakh L., Ciccenas S., Szszesna A., Juhasz E., Esteban-Gonzalez E., Molinier O., Klingelschmitt G., and Giaccone G. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J. Clin. Oncol. 27 (2009) 8001 (Abstract)
14. Charpidou A., Blatza D., Anagnostou V., and Syrigos K.N. Review. EGFR mutations in non-small cell lung cancer. Clinical implications. In Vivo 22 (2008) 529-536
15. Cohen B.D., Baker D.A., Soderstrom C., Tkalcevic G., Rossi A.M., Miller P.E., Tengowski M.W., Wang F., Gualberto A., Beebe J.S., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11 (2005) 2063-2073
16. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., Pinto A., and Normanno N. The role of the EGFR signaling in tumor microenvironment. J. Cell Physiol. 214 (2008) 559-567
17. Fukuoka M., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., Watkins C., Duffield E., Armour A., and Mok T. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients with advanced NSCLC. J. Clin. Oncol. 27 (2009) 8006 (Abstract)
18. Garçon N., Chomez P., and Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert. Rev. Vaccines 6 (2007) 723-739
19. Gettinger S. Targeted therapy in advanced non-small-cell lung cancer. Semin. Respir. Crit. Care Med. 29 (2008) 291-301
20. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2007) 641-648
21. Goldman B., and DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol. 27 (2009) 129-139
22. Heist R.S., and Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10 (2009) 59-68
23. Hida T., Ogawa S., Park J.C., Park J.Y., Shimizu J., Horio Y., and Yoshida K. Gefitinib for the treatment of non-small-cell lung cancer. Expert. Rev. Anticancer Ther. 9 (2009) 17-35
24. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Di Maria M.V., Veve R., Bremmes R.M., Baron A.E., Zeng C., and Franklin W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21 (2003) 3798-3807
25. Horn L., and Sandler A.B. Angiogenesis in the treatment of non-small cell lung cancer. Proc. Am. Thorac. Soc. 6 (2009) 206-217
26. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., Chambost H., Vitale M., Moretta A., Boon T., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
27. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
28. Johnson B.F., Clay T.M., Hobeika A.C., Lyerly H.K., and Morse M.A. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert. Opin. Biol. Ther. 7 (2007) 449-460
29. Karp D.D., Paz-Ares L.G., Novello S., Haluska P., Garland L., Cardenal F., Blakely L.J., Eisenberg P.D., Langer C.J., Blumenschein Jr. G., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 27 (2009) 2516-2522
30. Katzel J.A., Fanucchi M.P., and Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J. Hematol. Oncol. 2 (2009) 2
31. Kim E.S., Mauer A.M., William Jr. W.N., Tran H.T., Liu D., Lee J.J., Windt P., Hong W.K., Vokes E.E., and Herbst R.S. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115 (2009) 1713-1722
32. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
33. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
34. Krieg A.M. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117 (2007) 1184-1194
35. Kruit W.H., Suciu S., Dreno B., Chiarion-Sileni V., Mortier L., Robert C., Maio M., Brichard V., Lehmann F., and Keilholz U. Immunization with recombinant MAGE-A3 protein combined with Adjuvant Systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC melanoma group. J. Clin. Oncol. 26 (2008) 9065 (Abstract)
36. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., and Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9 (2008) 962-972
37. Louahed J., Gruselle O., Gaulis T., Coche T., Eggermont A.M., Kruit W., Dreno B., Chiarion S., Lehmann F., and Brichard V. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J. Clin. Oncol. 26 (2008) 9045 (Abstract)
38. Lucas S., and Coulie P.G. About human tumor antigens to be used in immunotherapy. Semin. Immunol. 20 (2008) 301-307
39. Ludovini V., Bellezza G., Pistola L., Bianconi F., Di C.L., Sidoni A., Semeraro A., Del Sordo R., Tofanetti F.R., Mameli M.G., et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann. Oncol. 20 (2009) 842-849
40. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert. Rev. Anticancer Ther. 8 (2008) 689-699
41. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., Hakansson L., van Baren N., Humblet Y., Mulders P., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39 (2003) 70-77
42. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 6 (2000) 4055-4063
43. Nemunaitis J., Dillman R.O., Schwarzenberger P.O., Senzer N., Cunningham C., Cutler J., Tong A., Kumar P., Pappen B., Hamilton C., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 4721-4730
44. Neninger Vinageras E., de la Torre A., Osorio Rodriguez M., Catalá Ferrer M., Bravo I., Mendoza del Pino M., Abreu Abreu D., Acosta Brooks S., Rives R., del Castillo Carrillo C., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol. 26 (2008) 1452-1458
45. Neninger E., Verdecia B.G., Crombet T., Viada C., Pereda S., Leonard I., Mazorra Z., Fleites G., Gonzalez M., Wilkinson B., et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 32 (2009) 92-99
46. O'Callaghan D., Rexhepaj E., Gately K., Gallagher W.M., Delaney D., Kay E., and O'Byrne K. Effect of pattern of lymphocyte infiltration in NSCLC on outcome. J. Clin. Oncol. 27 (2009) 11079 (Abstract)
47. Ozao-Choy J., Ma G., Kao J., Wang G.X., Meseck M., Sung M., Schwartz M., Divino C.M., Pan P.Y., and Chen S.H. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69 (2009) 2514-2522
48. Paccagnella A., Oniga F., Bearz A., Favaretto A., Clerici M., Barbieri F., Riccardi A., Chella A., Tirelli U., Ceresoli G., et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J. Clin. Oncol. 24 (2006) 681-687
49. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560 (2005) 11-18
50. Pennell N.A., and Lynch Jr. T.J. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14 (2009) 399-411
51. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., Dunant A., Torri V., Rosell R., Seymour L., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol. 26 (2008) 3552-3559
52. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., Vynnychenko I., Park K., Yu C.T., Ganul V., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373 (2009) 1525-1531
53. Rami-Porta R., Ball D., Crowley J., Giroux D.J., Jett J., Travis W.D., Tsuboi M., Vallières E., and Goldsrtaw P. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TMN classification for lung cancer. J. Thorac. Oncol. 2 (2007) 593-602
54. Ramlau R., Quoix E., Rolski J., Pless M., Lena H., Levy E., Krzakowski M., Hess D., Tartour E., Chenard M.P., et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J. Thorac. Oncol. 3 (2008) 735-744
55. Reck M., Macha H.N., Del Barco S., Cornes P., Vaissiere N., Morand M., Riggi M., and Abratt R. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 64 (2009) 319-325
56. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., Pfeifer W., O'Byrne K.J., Welte T., Kolb R., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19 (2008) 362-369
57. Salam I.A., Gaballa H.E., and Wahab N.A. Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med. Oncol. 26 (2009) 161-166
58. Salem M.L., Kadima A.N., El-Naggar S.A., Rubinstein M.P., Chen Y., Gillanders W.E., and Cole D.J. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30 (2007) 40-53
59. Salmon S., Chen H., Chen S., Herbst R., Tsao A., Tran H., Sandler A., Billheimer D., Shyr Y., Lee J.W., et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J. Thorac. Oncol. 4 (2009) 689-696
60. Sequist L.V., Bell D.W., Lynch T.J., and Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25 (2007) 587-595
61. Silvestri G.A., and Rivera M.P. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128 (2005) 3975-3984
62. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115 (2005) 739-746
63. Stinchcombe T.E., and Socinski M.A. Current treatments for advanced stage non-small cell lung cancer. Proc. Am. Thorac. Soc. 6 (2009) 233-241
64. Taguchi F., Solomon B., Gregorc V., Roder H., Gray R., Kasahara K., Nishio M., Brahmer J., Spreafico A., Ludovini V., et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl. Cancer Inst. 99 (2007) 838-846
65. van der Bruggen P., Bastin J., Gajewski T., Coulie P.G., Boel P., de Smet C., Traversari C., Townsend A., and Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24 (1994) 3038-3043
66. Vansteenkiste J., Zielinski M., Linder A., Dahabreh I.J., Esteban E., Malinowski W., Jassem J., Passlick B., Lehmann F., and Brichard V. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25 (2007) 7554 (Abstract)
67. Vansteenkiste J., Zielinski M., Linder A., Dahabreh I.J., Esteban E., Malinowski W., Jassem J., Passlick B., Lehmann F., and Brichard V. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26 (2008) 9045 (Abstract)
68. Vantomme V., Dantinne C., Amrani N., Permanne P., Gheysen D., Bruck C., Stoter G., Britten C.M., Keilholz U., Lamers C.H., et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother. 27 (2004) 124-135
69. Yamashita S., Chujo M., Miyawaki M., Tokuishi K., Anami K., Yamamoto S., and Kawahara K. Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 28 (2009) 22
70. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., Yang P.C., and Lee Y.C. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 19 (2001) 432-441
71. Zitvogel L., Apetoh L., Ghiringhelli F., and Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8 (2008) 59-73